Skip to content

Search for:

Search for:
Contacts
IT
EN

Toggle Navigation

About us
Areas of intervention
Transplant

Transplantation Therapeutical Solutions

Critical Care

Critical Care Therapeutical Solutions

Pathologies
- Transplant
  - Transplantation Therapeutical Solutions
- Critical Care
  - Critical Care Therapeutical Solutions
  - Pathologies
Scientific Literature
- PerTransplantation Gallery
News
Events
Purification Therapies
Contacts
Search for:

F.D.A. (USA) Approved for Emergency CytoSorb^® 300 mL Device Treatment of COVID-19

F.D.A. (USA) Approved for Emergency CytoSorb^® 300 mL Device Treatment of COVID-19

Selection of the press release 2020

Download press release

Aferetica2020-05-14T13:00:25+02:0014 May 2020|Press review|

Facebook X Reddit LinkedIn WhatsApp Telegram Tumblr Pinterest Vk Xing Email

Keep in touch!

Sign up for our newsletter!

Copyright Aferetica srl | All Rights Reserved
Website by BauWeb | Mec&Partners

Headquarters:
Via Roma 19 40017
San Giovanni in Persiceto (BO)

Registered Office:
Aferetica s.r.l.
Via Spartaco 10 40138 Bologna

Tel: +39 0535 640261
P.I./VAT 03330561204

For more information, contact our Customer Service:
customer.service@aferetica.com

Tel: +39 0535 640263
Fax: +39 051 0218364

Whistleblowing
Privacy Policy
Cookies Policy